Рынок лечения фиброза печени в Европе: размер, тенденции, отчет о росте 2032 года.

Europe Liver Fibrosis Treatment Market

Размер рынка в млрд долларов США

CAGR : 10.30 %

USD 5.06 Billion USD 11.04 Billion 2024 2032

Прогнозируемый период	2025 –2032
Размер рынка (базовый год)	USD 5.06 Billion
Размер рынка (прогнозируемый год)	USD 11.04 Billion
CAGR	10.30 %
Основные игроки рынка	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Запрос на разблокировку

Европейский рынок лечения фиброза печени по типу лечения (медикаментозное и хирургическое/терапевтическое), стадиям (F2, F1, F3 и F4), показаниям (неалкогольный стеатогепатит (НАСГ), фиброз, вызванный гепатитом B и C, алкогольная болезнь печени (АБП), аутоиммунные заболевания печени, генетические нарушения и другие), полу (мужчины и женщины), конечному пользователю (больницы, специализированные клиники, клиники, амбулаторные и исследовательские центры и другие), каналу сбыта (прямые торги и розничные продажи) — тенденции отрасли и прогноз до 2032 г.

Размер рынка лечения фиброза печени в Европе

Европейский рынок лечения фиброза печени в 2024 году оценивался в 5,06 млрд долларов США , а к 2032 году, как ожидается, достигнет 11,04 млрд долларов США .
В прогнозируемый период с 2025 по 2032 год рынок, вероятно, будет расти среднегодовыми темпами в 10,3%, в первую очередь за счет повышения осведомленности потребителей о натуральных решениях для здоровья.
Этот рост обусловлен такими факторами, как рост распространенности заболеваний печени. Кроме того, доступность стимулирует рост потребления алкоголя.

Анализ рынка лечения фиброза печени в Европе

Растущее число заболеваний печени приводит к увеличению числа пациентов, которым требуются эффективные варианты лечения, особенно при таких заболеваниях, как гепатит В и С. Такие способствующие факторы, как рост потребления алкоголя, нездоровые привычки питания и рост показателей ожирения, привели к увеличению числа людей, у которых диагностируют эти заболевания печени.
По мере прогрессирования поражения печени риск развития фиброза печени увеличивается, что создает значительную нагрузку на системы здравоохранения, предлагая эффективные варианты лечения. Этот растущий спрос стимулирует разработку и доступность целевых методов лечения, подпитывая рост рынка, поскольку поставщики медицинских услуг ищут инновационные решения для управления этим состоянием
Более того, возросшая осведомленность среди врачей и широкой общественности привела к тому, что больше людей прошли скрининг и диагностику на ранних стадиях заболевания печени. Достижения в диагностических методах, включая неинвазивную визуализацию и анализы крови, способствовали выявлению фиброза печени на более ранних стадиях развития заболевания. Такое раннее обнаружение позволяет проводить своевременные вмешательства, стимулируя спрос на инновационные методы лечения, которые эффективно обращают вспять или контролируют фиброз печени.

Например, в августе 2023 года, согласно статье, опубликованной NCBI, заболевания печени ежегодно становятся причиной двух миллионов смертей и являются причиной 4% всех смертей (1 из каждых 25 смертей в мире); примерно две трети всех смертей, связанных с печенью, происходят среди мужчин. Эта тревожная статистика подчеркивает острую необходимость в эффективных вариантах лечения и подчеркивает значительное бремя для общественного здравоохранения, создаваемое заболеваниями печени, что еще больше мотивирует системы здравоохранения и фармацевтические компании уделять первоочередное внимание разработке инновационных методов лечения, специально нацеленных на фиброз печени и его основные причины.

Следовательно, фармацевтические компании и медицинские исследователи вынуждены инвестировать в разработку новых терапевтических вариантов, тем самым стимулируя рынок, поскольку заинтересованные стороны стремятся бороться с растущей заболеваемостью печени и связанными с ними осложнениями.

Область применения отчета и сегментация европейского рынка лечения фиброза печени

Атрибуты	Ключевые данные о мировом рынке лечения фиброза печени
Охваченные сегменты	По типу лечения Медикамент Хирургия/терапия Этапы Ф2 Ф1 F3 Ф4 Индикация Неалкогольный стеатогепатит (НАСГ) Фиброз, вызванный гепатитом В и С Алкогольная болезнь печени (АБП) Аутоиммунные заболевания печени Генетические нарушения Другие Пол Мужской Женский Конечный пользователь Больницы Специализированные клиники Клиники Амбулаторные и исследовательские центры Другие Канал распространения Прямой тендер Розничные продажи
Страны, охваченные	Северная Америка ВШЬ Канада Мексика Европа Германия Франция Великобритания Италия Испания Швейцария Россия Бельгия Нидерланды Турция Польша Швеция Норвегия Дания Финляндия Остальная Европа Азиатско-Тихоокеанский регион Китай Япония Индия Южная Корея Австралия Сингапур Таиланд Индонезия Малайзия Тайвань Новая Зеландия Филиппины Вьетнам Остальная часть Азиатско-Тихоокеанского региона Южная Америка Бразилия Аргентина Остальная часть Южной Америки Ближний Восток и Африка ЮАР Саудовская Аравия ОАЭ Египет Израиль Кувейт Катар Оман Остальной Ближний Восток и Африка
Ключевые игроки рынка	F. Hoffmann-La Roche Ltd (Швейцария) Эбботт (США) La Renon Healthcare Pvt. Ltd. (Индия) GENFIT SA (Франция) Madrigal Pharmaceuticals (США) Aligos Therapeutics (США) Pfizer Inc. (США) Энанта Фармасьютикалс, Инк. (США) Компания Bristol-Myers Squibb (США) Vertex Pharmaceuticals Incorporated (США) Takeda Pharmaceutical Company Limited (Япония) Hepion Pharmaceuticals (США) Echosens (Франция) Galectin Therapeutics, Inc. (США) Conatus Pharmaceuticals (США) Tvardi Therapeutics (США) Viking Therapeutics (США) Calliditas Therapeutics AB (Швеция) Новомедикс (США) Galecto Biotech (Дания) Pilant Therapeutics, Inc. (США) Sagimet Biosciences (США) Gyre Therapeutics, Inc. (США) Akero Therapeutics, Inc. (США) CureVac SE (Германия) Novo Nordisk A/S (Дания) Ипсен Фарма (Франция) AdAlta Limited (Австралия) Alentis Therapeutics AG (Швейцария) Gilead Sciences, Inc. (США) AbbVie Inc. (США) Merck and Co., Inc. (США) Новартис АГ (Швейцария) Intercept Pharmaceuticals, Inc. (США)
Возможности рынка	Новые технологии и передовые методы лечения фиброза печени Прогресс в разработке препаратов для лечения фиброза печени Стратегические слияния и поглощения среди ключевых игроков
Информационные наборы данных с добавленной стоимостью	Помимо информации о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, подготовленные Data Bridge Market Research, также включают анализ импорта и экспорта, обзор производственных мощностей, анализ потребления продукции, анализ ценовых тенденций, сценарий изменения климата, анализ цепочки поставок, анализ цепочки создания стоимости, обзор сырья и расходных материалов, критерии выбора поставщиков, анализ PESTLE, анализ Портера и нормативную базу.

Тенденции европейского рынка лечения фиброза печени

«Растущий уровень заболеваемости печенкой»

Растущая распространенность заболеваний печени становится серьезной проблемой мирового здравоохранения, существенно увеличивая нагрузку на здравоохранение во всем мире.
Такие факторы, как чрезмерное употребление алкоголя, рост уровня ожирения, вирусные гепатиты и нездоровый образ жизни приводят к росту таких заболеваний, как жировая болезнь печени, цирроз и рак печени.
Растущая заболеваемость неалкогольной жировой болезнью печени (НАЖБП), особенно связанной с диабетом и метаболическим синдромом, также вызывает тревогу. В результате растет спрос на раннюю диагностику, эффективные варианты лечения и инициативы в области общественного здравоохранения. Ожидается, что эта тенденция будет стимулировать инновации и рост на рынке лечения заболеваний печени

Динамика рынка лечения фиброза печени в Европе

Драйверы

«Рост потребления алкоголя»

Рост потребления алкоголя вносит значительный вклад в мировой рынок лечения фиброза печени из-за его прямой связи с заболеваемостью печени, в частности алкогольной болезнью печени (АБП).
Поскольку все больше людей употребляют алкоголь регулярно и в больших количествах, риск развития осложнений, связанных с печенью, включая фиброз и цирроз печени, значительно возрастает.
Хронический алкоголизм приводит к воспалению, накоплению жира и, в конечном итоге, фиброзу, поскольку печень подвергается повторяющимся повреждениям и восстановлению.
Растущая распространенность заболеваний печени, связанных с алкоголем, создает острую потребность в эффективных методах лечения и стратегиях управления, которые помогут смягчить повреждение печени и улучшить результаты лечения пациентов.

Например,

В октябре 2024 года, согласно статье, опубликованной в International Journal of Mental Health Systems, распространенность потребления алкоголя составляла 54,5% и 47,7% на исходном уровне и в ходе последующего наблюдения соответственно. Более того, 12% мужчин сообщили, что начали пить впервые. Такая распространенность потребления алкоголя приводит к увеличению заболеваемости фиброзом печени во всем мире, что может повлиять на рост рынка
По данным STAT, в июне 2024 года число смертей, связанных с алкоголем, растет, и эксперты особенно обеспокоены ростом среди молодежи и женщин. В США в период с 2019 по 2020 год число смертей, связанных с алкоголем, возросло на 25,5%, что составляет 3% от всех смертей. Более того, наибольший рост числа смертей, связанных с алкоголем, наблюдался среди людей в возрасте от 25 до 34 и от 35 до 44 лет, причем число смертей в обеих группах увеличилось более чем на 37%.
Более того, растущее общественное признание и нормализация потребления алкоголя, особенно среди молодежи, еще больше усугубляют проблему, приводя к увеличению числа людей, подверженных риску фиброзных изменений печени.
Эта тенденция способствует росту рынка лечения фиброза печени и подчеркивает важность инициатив общественного здравоохранения, направленных на снижение потребления алкоголя и профилактику заболеваний печени.

Возможности

«Новейшие технологии и передовые методы лечения фиброза печени»

Новые технологии, такие как генная терапия, целевая молекулярная терапия и биологические агенты, трансформируют ландшафт лечения.
Последние инновации сосредоточены на препаратах, которые специально нацелены на пути прогрессирования фиброза, таких как агонисты FXR, ингибиторы TGF-β и противовоспалительные средства. Кроме того, неинвазивные диагностические инструменты, такие как эластография, улучшают раннее обнаружение
Эти достижения предлагают более эффективные, персонализированные методы лечения таких заболеваний, как НАСГ (неалкогольный стеатогепатит) и цирроз, что приводит к лучшим результатам для пациентов.

В феврале 2024 года в Springer Nature была опубликована статья, в которой рассматриваются новые подходы к диагностике и ингибированию фиброгенеза печени. Достижения включают неинвазивные биомаркеры, технологии визуализации и клеточную терапию, такую как мезенхимальные стволовые клетки. Перспективные антифибротические препараты, включая пирфенидон и обетихолиновую кислоту, а также инновации в области тканевой инженерии, нанотехнологий и микрофлюидных моделей, демонстрируют потенциал для персонализированного, точного лечения
В статье NCBI от сентября 2021 года подчеркивается, что новые технологии в лечении фиброза печени сосредоточены на передовых методах лечения, нацеленных на молекулярные пути, такие как активация звездчатых клеток печени. Такие инновации, как генная терапия, биопрепараты, ингибиторы малых молекул и неинвазивная диагностика, улучшают раннее выявление и лечение. Терапия стволовыми клетками и тканевая инженерия также обещают обратить вспять фиброз и улучшить восстановление

Благодаря постоянному развитию стратегий лечения и диагностических технологий методы лечения фиброза печени стремительно развиваются.
Эти инновации дают надежду на более эффективное лечение заболеваний печени, гарантируя пациентам доступ к более эффективным, персонализированным методам лечения с меньшим количеством побочных эффектов, что в конечном итоге улучшает глобальные результаты в области здравоохранения.

Ограничения/Вызов

« Ограниченная осведомленность о заболеваниях печени»

Ограниченная осведомленность о заболеваниях печени препятствует ранней диагностике и соответствующему вмешательству. Многие люди не знают о факторах риска и симптомах, связанных с заболеваниями печени, часто приписывая неясные признаки болезни другим, менее серьезным проблемам
Из-за отсутствия знаний медицинские консультации откладываются до тех пор, пока болезнь не перейдет в поздние стадии, такие как фиброз печени или цирроз, когда варианты лечения становятся более сложными и менее эффективными.
Следовательно, поздняя диагностика снижает вероятность успешного лечения и ограничивает общий рост рынка, ограничивая количество пациентов, обращающихся за своевременной помощью.

Например,

В апреле 2024 года Люпин заявил, что пациенты не знают о своем состоянии, пока болезнь не достигнет критической стадии, что вызвало острую необходимость пересмотреть подход к осведомленности, выявлению и лечению заболеваний печени. Однако существенным препятствием в лечении заболеваний печени является ограниченное понимание заболеваний печени и связанных с ними факторов риска.
В июле 2021 года, согласно исследованию, в котором приняли участие 11 700 взрослых (18+ лет) из пяти Национальных обследований здоровья и питания, почти 96% взрослых с НАЖБП в США не знали, что у них есть заболевание печени, особенно среди молодых людей. Поэтому повышение осведомленности и просвещения о здоровье печени имеет решающее значение для улучшения результатов лечения пациентов и содействия более активному подходу к лечению фиброза печени и расширению рынка лечения
В январе 2021 года Springer Nature сообщил, что среди 825 пациентов, включенных в анализ исследования, проведенного в исследовательской статье «Недостаточная осведомленность о повреждении органов печени у пациентов с диабетом 2 типа», 8,1% (95% ДИ 5,1%-12,7%) пациентов со стеатозом знали о наличии у них заболевания печени. Более того, в общенациональной репрезентативной выборке взрослых в США с СД2 распространенность выраженного фиброза печени высока. Менее 20% пациентов с выраженным фиброзом знают о наличии у них какого-либо заболевания печени
Ограниченная осведомленность затрудняет потенциальные результаты лечения пациентов и сдерживает рост рынка, сокращая число людей, обращающихся за услугами здравоохранения на ранних этапах.
Таким образом, повышение осведомленности и просвещения в вопросах здоровья печени имеет решающее значение для улучшения ранней диагностики, повышения эффективности лечения и, в конечном итоге, для создания более устойчивого рынка методов лечения фиброза печени.

Объем рынка лечения фиброза печени в Европе

Рынок сегментирован по типу лечения, стадиям, показаниям, конечному потребителю и каналу сбыта.

Сегментация	Субсегментация
По типу лечения	Тип лечения Медикамент Хирургия/терапия
По этапам	Этапы Ф2 Ф1 F3 Ф4
По показаниям	Индикация Неалкогольный стеатогепатит (НАСГ) Фиброз, вызванный гепатитом B и C Алкогольная болезнь печени (АБП) Аутоиммунные заболевания печени Генетические нарушения Другие.
Конечным пользователем	Конечный пользователь Больницы Специализированные клиники Клиники Амбулаторные и исследовательские центры Другие
По каналу распространения	Канал распространения Прямой тендер Розничные продажи

Региональный анализ рынка лечения фиброза печени в Европе

«Германия — доминирующий регион на рынке мэйнфреймов»

Германия лидирует на рынке лечения фиброза печени в Европе благодаря своей надежной инфраструктуре здравоохранения, высокой распространенности заболеваний печени и сильному акценту на ранней диагностике и стратегиях вмешательства.
Страна пользуется преимуществами обширного охвата услугами здравоохранения, устоявшейся политики возмещения расходов и растущего спроса на неинвазивные методы диагностики и лечения.
Лидерство Германии в клинических исследованиях и ее активное участие в кампаниях по повышению осведомленности о заболеваниях печени дополнительно способствуют росту рынка
Растущее внедрение передовых методов лечения, повышение осведомленности пациентов и правительственные инициативы по борьбе с хроническими заболеваниями печени способствуют доминированию Германии в регионе.

«Прогнозируется, что Германия зарегистрирует самые высокие темпы роста»

Германия также является самым быстрорастущим рынком, чему способствуют постоянные инновации в области биомаркеров фиброза, увеличение инвестиций в НИОКР со стороны фармацевтических компаний и рост числа случаев алкогольной и неалкогольной жировой болезни печени.
В совокупности эти факторы позиционируют Германию как центр лечения фиброза печени в Европе, что делает ее крупнейшим и наиболее быстрорастущим рынком в регионе.

Доля рынка лечения фиброза печени в Европе

Конкурентная среда рынка содержит сведения о конкурентах. Включены сведения о компании, финансы компании, полученный доход, рыночный потенциал, инвестиции в исследования и разработки, новые рыночные инициативы, присутствие в Европе, производственные площадки и объекты, производственные мощности, сильные и слабые стороны компании, запуск продукта, широта и широта продукта, доминирование приложений. Приведенные выше данные относятся только к фокусу компаний на рынке.

Основными лидерами рынка, работающими на рынке, являются:

F. Hoffmann-La Roche Ltd (Швейцария)
Эбботт (США)
La Renon Healthcare Pvt. Ltd. (Индия)
GENFIT SA (Франция)
Madrigal Pharmaceuticals (США)
Aligos Therapeutics (США)
Pfizer Inc. (США)
Энанта Фармасьютикалс, Инк. (США)
Компания Bristol-Myers Squibb (США)
Vertex Pharmaceuticals Incorporated (США)
Takeda Pharmaceutical Company Limited (Япония)
Hepion Pharmaceuticals (США)
Echosens (Франция)
Galectin Therapeutics, Inc. (США)
Conatus Pharmaceuticals (США)
Tvardi Therapeutics (США)
Viking Therapeutics (США)
Calliditas Therapeutics AB (Швеция)
Новомедикс (США)
Galecto Biotech (Дания)
Pilant Therapeutics, Inc. (США)
Sagimet Biosciences (США)
Gyre Therapeutics, Inc. (США)
Akero Therapeutics, Inc. (США)
CureVac SE (Германия)
Novo Nordisk A/S (Дания)
Ипсен Фарма (Франция)
AdAlta Limited (Австралия)
Alentis Therapeutics AG (Швейцария)
Gilead Sciences, Inc. (США)
AbbVie Inc. (США)
Merck & Co., Inc. (США)
Новартис АГ (Швейцария)
Intercept Pharmaceuticals, Inc. (США)

Последние разработки на европейском рынке лечения фиброза печени

В июне 2024 года компания Gilead Sciences представила новое исследование на Конгрессе Европейской ассоциации по изучению печени (EASL) 2024 года в Милане, сосредоточившись на таких заболеваниях печени, как первичный билиарный холангит (ПБХ), гепатит В (ГВ), вирус гепатита дельта (ВГД) и других. Основные презентации будут включать долгосрочные данные исследования ASSURE по селаделпару для ПБХ, результаты по тенофовиру для профилактики рака печени при ВГВ и выводы исследований MYR204 и MYR301 по Hepcludex для ВГД. Это исследование подчеркивает приверженность Gilead продвижению вариантов лечения заболеваний печени
В октябре 2024 года компания Intercept Pharmaceuticals, Inc. обсудила свои текущие усилия по изучению расовых различий и неравенства в лечении первичного билиарного холангита (ПБХ). Компания изучает, как различные группы населения могут сталкиваться с различными проблемами в диагностике, лечении и ведении ПБХ. Изучая эти различия, Intercept стремится улучшить доступ к уходу и результатам лечения для всех пациентов, потенциально снижая барьеры для эффективного лечения заболеваний печени, включая фиброз
В ноябре 2022 года Управление по контролю за продуктами и лекарствами США (FDA) одобрило препарат Вемлиди (тенофовир алафенамид) для лечения хронической инфекции вируса гепатита В (HBV) у детей в возрасте 12 лет и старше с компенсированным заболеванием печени. Это одобрение расширяет применение препарата Вемлиди, который был первоначально одобрен в 2016 году для взрослых с хроническим HBV. Одобрение основано на клиническом исследовании фазы 2, демонстрирующем эффективность и безопасность препарата Вемлиди у этой группы пациентов младшего возраста.
В сентябре 2022 года Gilead Sciences завершила приобретение MiroBio, британской биотехнологической компании, занимающейся восстановлением иммунного баланса с помощью агонистов, воздействующих на иммуноингибиторные рецепторы. Приобретение, стоимостью около 405 миллионов долларов, предоставляет Gilead платформу для исследований MiroBio и ее портфель агонистов иммуноингибиторных рецепторов. Ведущее исследуемое антитело MiroBio, MB272, воздействует на иммунные клетки, подавляя воспалительные иммунные реакции, и в настоящее время проходит фазу 1 клинических испытаний. Это приобретение усиливает усилия Gilead по борьбе с хроническими иммуноопосредованными состояниями
В марте 2021 года Gilead Sciences и Novo Nordisk расширили свое сотрудничество в лечении неалкогольного стеатогепатита (НАСГ), начав клиническое исследование фазы 2b. Исследование изучает безопасность и эффективность семаглутида, агониста рецептора GLP-1 от Novo Nordisk, в сочетании с цилофексором (агонистом FXR) и фирсокостатом (ингибитором ACC) от Gilead у пациентов с циррозом, вызванным НАСГ. В исследовании будет оцениваться влияние лечения на фиброз печени и разрешение НАСГ, а набор пациентов, как ожидается, начнется во второй половине 2021 года.

SKU-73829

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Интерактивная панель анализа данных
Панель анализа компании для возможностей с высоким потенциалом роста
Доступ аналитика-исследователя для настройки и запросов
Анализ конкурентов с помощью интерактивной панели
Последние новости, обновления и анализ тенденций
Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов

Запросить демонстрацию

Содержание

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE EUROPE LIVER FIBROSIS TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 MULTIVARIATE MODELLING

2.6 TREATMENT TYPE LIFELINE CURVE

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSIS

4.2 PORTERS FIVE FORCES ANALYSIS

4.2.1 LIVER TRANSPLANTATION VOLUME AND THEIR COST FOR LIVER FIBROSIS BY COUNTRY

4.2.2 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES FOR LIVER FIBROSIS: VOLUME AND COST BY COUNTRY

4.2.3 PARTIAL HEPATECTOMY (LIVER RESECTION) COST BY COUNTRY

4.2.4 CELL-BASED THERAPY COST FOR LIVER FIBROSIS TREATMENT BY COUNTRY

4.3 EPIDEMIOLOGY

4.3.1 INCIDENCE OF ALL BY GENDER

4.3.2 TREATMENT RATE

4.3.3 TREATMENT RATE

4.3.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

4.3.5 PATIENT TREATMENT SUCCESS RATES

4.4 MARKETED DRUG ANALYSIS

4.5 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

4.5.1 PATIENT FLOW DIAGRAM

4.5.2 KEY PRICING STRATEGIES

4.5.3 KEY PATIENT ENROLLMENT STRATEGIES

5 EUROPE LIVER FIBROSIS TREATMENT MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF LIVER DISEASES

6.1.2 RISING CONSUMPTION OF ALCOHOL

6.1.3 RISING LIVER TRANSPLANTATION RATES

6.1.4 GROWING INCIDENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) & NASH

6.2 RESTRAINTS

6.2.1 LIMITED AWARENESS OF LIVER DISEASES

6.2.2 REGULATORY CHALLENGES

6.3 OPPORTUNITIES

6.3.1 EMERGING TECHNOLOGIES AND ADVANCED TREATMENTS IN LIVER FIBROSIS MANAGEMENT

6.3.2 PROGRESS IN PIPELINE PRODUCTS FOR LIVER FIBROSIS TREATMENT

6.3.3 STRATEGIC MERGERS AND ACQUISITIONS AMONG THE KEY PLAYERS

6.4 CHALLENGES

6.4.1 LACK OF EFFECTIVE AND APPROVED ANTI-FIBROTIC DRUGS

6.4.2 HIGH COST OF TREATMENTS IN LIVER FIBROSIS CARE

7 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE

7.1 OVERVIEW

7.2 MEDICATION

7.2.1 ANTIVIRAL AGENTS

7.2.1.1 VELPATASVIR/SOFOSBUVIR

7.2.1.2 TENOFOVIR

7.2.1.3 LEDIPASVIR/SOFOSBUVIR

7.2.1.4 SOFOSBUVIR

7.2.1.5 ENTECAVIR

7.2.2 ANTIFIBROTIC AGENTS

7.2.2.1 OBETICHOLIC ACID

7.2.2.2 TGF-Β INHIBITORS

7.2.2.3 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) INHIBITORS

7.2.2.4 LYSYL OXIDASE-LIKE 2 (LOXL2) INHIBITORS

7.2.2.5 OTHERS

7.2.3 ANTI-INFLAMMATORY DRUGS

7.2.3.1 CORTICOSTEROIDS

7.2.3.1.1 PREDNISONE

7.2.3.1.2 DEXAMETHASONE

7.2.3.2 TUMOR NECROSIS FACTOR (TNF) INHIBITORS

7.2.3.2.1 INFLIXIMAB

7.2.3.2.2 ETANERCEPT

7.2.3.3 INTERLEUKIN (IL) INHIBITORS

7.2.3.3.1 IL-6 INHIBITORS (TOCILIZUMAB)

7.2.3.3.2 IL-1 INHIBITORS (ANAKINRA)

7.2.4 IMMUNOSUPPRESSANTS

7.2.4.1 MYCOPHENOLATE MOFETIL

7.2.4.2 TACROLIMUS

7.2.4.3 CYCLOSPORINE

7.2.5 MARKETED DRUGS

7.2.5.1 VELPATASVIR/SOFOSBUVIR

7.2.5.2 TENOFOVIR

7.2.5.3 LEDIPASVIR/SOFOSBUVIR

7.2.5.4 OBETICHOLIC ACID (OCA)

7.2.5.5 SOFOSBUVIR

7.2.5.6 PIRFENIDONE

7.2.5.7 OTHERS

7.2.6 PIPELINE DRUGS

7.2.7 BRANDED DRUGS

7.2.7.1 EPCLUSA

7.2.7.2 VIREAD AND VEMLIDY

7.2.7.3 OCALIVA

7.2.7.4 HARVONI

7.2.7.5 SOVALDI

7.2.7.6 BARACLUDE

7.2.7.7 ACTOS

7.2.7.8 OTHERS

7.2.8 GENERIC DRUGS

7.2.9 ORAL

7.2.10 PARENTERAL

7.2.11 OTHERS

7.3 SURGERY/THERAPY

7.3.1 LIVER TRANSPLANTATION

7.3.2 ORTHOTOPIC LIVER TRANSPLANT (OLT)

7.3.3 LIVING DONOR LIVER TRANSPLANT (LDLT)

7.3.4 SPLIT LIVER TRANSPLANTATION

7.3.5 DOMINO LIVER TRANSPLANT

7.3.6 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES

7.3.6.1 ENDOSCOPIC VARICEAL LIGATION (EVL)

7.3.6.2 TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS)

7.3.6.3 LIVER ABLATION PROCEDURES

7.3.6.3.1 RADIOFREQUENCY ABLATION (RFA)

7.3.6.3.2 MICROWAVE ABLATION (MWA)

7.3.7 PARTIAL HEPATECTOMY (LIVER RESECTION)

7.3.7.1 SEGMENTAL RESECTION

7.3.7.2 LOBECTOMY

7.3.7.3 WEDGE RESECTION

7.3.8 CELL-BASED THERAPY

7.3.8.1 STEM CELL THERAPY

7.3.8.1.1 MESENCHYMAL STEM CELLS (MSCS)

7.3.8.1.2 HEMATOPOIETIC STEM CELLS (HSCS)

7.3.8.2 GENE THERAPY

7.3.8.2.1 CRISPR-BASED LIVER REGENERATION

7.3.8.2.2 HEPATIC STELLATE CELL (HSC) INHIBITORS

7.3.8.2.3 SIRNA-BASED THERAPIES

7.3.8.2.4 HEPATOCYTE APOPTOSIS INHIBITORS

7.3.8.2.4.1 OXIDATIVE STRESS INHIBITORS

7.3.8.2.4.2 EMRICASAN

7.3.8.2.4.3 PENTOXIFYLLINE

7.3.8.2.4.4 LOSARTAN

7.3.8.2.4.5 METHYL FERULIC ACID

7.3.8.2.4.6 OTHERS

7.4 OTHERS

8 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY STAGES

8.1 OVERVIEW

8.2 F2

8.3 F1

8.4 F3

8.5 F4

9 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY INDICATION

9.1 OVERVIEW

9.2 NON-ALCOHOLIC STEATOHEPATITIS (NASH)

9.3 HEPATITIS B & C-INDUCED FIBROSIS

9.3.1 CHRONIC HEPATITIS B VIRUS (HBV) FIBROSIS

9.3.2 CHRONIC HEPATITIS C VIRUS (HCV) FIBROSIS

9.4 ALCOHOLIC LIVER DISEASE (ALD)

9.5 AUTOIMMUNE LIVER DISEASES

9.5.1 AUTOIMMUNE HEPATITIS (AIH)

9.5.2 PRIMARY BILIARY CHOLANGITIS (PBC)

9.5.3 PRIMARY SCLEROSING CHOLANGITIS (PSC)

9.6 GENETIC DISORDERS

9.6.1 HEMOCHROMATOSIS

9.6.2 WILSON’S DISEASE

9.6.3 ALPHA-1 ANTITRYPSIN DEFICIENCY

9.7 OTHERS

10 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY GENDER

10.1 OVERVIEW

10.2 MALE

10.2.1 40-55 YEARS

10.2.2 ABOVE 55 YEARS

10.2.3 BELOW 40 YEARS

10.3 FEMALE

10.3.1 ABOVE 55 YEARS

10.3.2 40-55 YEARS

10.3.3 BELOW 40 YEARS

11 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.2.1 PUBLIC HOSPITALS

11.2.2 PRIVATE HOSPITALS

11.3 SPECIALTY CLINICS

11.3.1 HEPATOLOGY CLINICS

11.3.2 GASTROENTEROLOGY CLINICS

11.4 CLINICS

11.5 AMBULATORY AND RESEARCH CENTERS

11.6 OTHERS

12 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.2.1 RETAIL SALES

12.2.1.1 HOSPITAL PHARMACY

12.2.1.2 RETAIL PHARMACY

12.2.1.3 ONLINE PHARMACY

13 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY REGION

13.1 EUROPE

13.1.1 GERMANY

13.1.2 FRANCE

13.1.3 U.K.

13.1.4 ITALY

13.1.5 SPAIN

13.1.6 SWITZERLAND

13.1.7 RUSSIA

13.1.8 BELGIUM

13.1.9 NETHERLANDS

13.1.10 TURKEY

13.1.11 POLAND

13.1.12 SWEDEN

13.1.13 NORWAY

13.1.14 DENMARK

13.1.15 FINLAND

13.1.16 REST OF EUROPE

14 EUROPE LIVER FIBROSIS TREATMENT MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: GLOBAL

15 SWOT ANALYSIS

16 COMPANY PROFILES

16.1 GILEAD SCIENCES, INC.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENT/NEWS

16.2 ABBVIE, INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENT

16.3 MERCK & CO, INC.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENT

16.4 NOVARTIS AG

16.4.1 COMPANY SNAPSHOTS

16.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 PIPELINE PRODUCT PORTFOLIO

16.4.6 RECENT DEVELOPMENT

16.5 INTERCEPT PHARMACEUTICALS, INC.

16.5.1 COMPANY SNAPSHOTS

16.5.2 COMPANY SHARE ANALYSIS

16.5.3 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 PIPELINE PRODUCT PORTFOLIO

16.5.6 RECENT NEWS

16.6 ABBOTT

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 1.1.5 RECENT DEVELOPMENT

16.7 ALIGOS THERAPEUTICS

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENT

16.8 ALNICHE LIFE SCIENCES PVT. LTD.

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 ALENTIS THERAPEUTICS AG

16.9.1 COMPANY SNAPSHOT

16.9.2 PIPELINE PRODUCT PORTFOLIO

16.9.3 RECENT DEVELOPMENT

16.1 ADALTA LIMITED

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PIPELINE PRODUCT PORTFOLIO

16.10.4 RECENT NEWS

16.11 AKERO THERAPEUTICS, INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PIPELINE PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 BRISTOL-MYERS SQUIBB

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 CALLIDITAS THERAPEUTICS AB

16.13.1 COMPANY SNAPSHOT

16.13.2 PIPELINE PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENT

16.14 CUREVAC SE

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENT

16.15 CONATUSPHARMA

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT/NEWS

16.16 ENANTA PHARMACEUTICALS, INC.

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENT

16.17 ECHOSENS

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENT/NEWS

16.18 F. HOFFMANN-LA ROCHE LTD

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 COMPANY SHARE ANALYSIS

16.18.4 PRODUCT PORTFOLIO

16.18.5 RECENT DEVELOPMENT

16.19 GALECTO BIOTECH

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PIPELINE PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENT/NEWS

16.2 GALECTIN THERAPEUTICS, INC.

16.20.1 COMPANY SNAPSHOTS

16.20.2 REVENUE ANALYSIS AND SEGMENTAL ANALYSIS

16.20.3 PIPELINE PRODUCT PORTFOLIO

16.20.4 RECENT DEVELOPMENT

16.21 GYRE THERAPEUTICS, INC.

16.21.1 COMPANY SNAPSHOT

16.21.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.21.3 PRODUCT PORTFOLIO

16.21.4 RECENT DEVELOPMENT/NEWS

16.22 GENFIT SA

16.22.1 COMPANY SNAPSHOTS

16.22.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.22.3 PIPELINE PRODUCT PORTFOLIO

16.22.4 RECENT DEVELOPMENT

16.23 HEPION PHARMACEUTICALS

16.23.1 COMPANY SNAPSHOT

16.23.2 REVENUE ANALYSIS

16.23.3 PIPELINE PORTFOLIO

16.23.4 RECENT DEVELOPMENT

16.24 IPSEN PHARMA

16.24.1 COMPANY SNAPSHOT

16.24.2 REVENUE ANALYSIS

16.24.3 PIPELINE PRODUCT PORTFOLIO

16.24.4 RECENT NEWS/DEVELOPMENTS

16.25 LA RENON HEALTHCARE PVT. LTD.

16.25.1 COMPANY SNAPSHOT

16.25.2 PRODUCT PORTFOLIO

16.25.3 RECENT DEVELOPMENT

16.26 MADRIGAL PHARMACEUTICALS

16.26.1 COMPANY SNAPSHOTS

16.26.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.26.3 PRODUCT PORTFOLIO

16.26.4 RECENT DEVELOPMENT

16.27 NOVO NORDISK A/S

16.27.1 COMPANY SNAPSHOT

16.27.2 REVENUE ANALYSIS

16.27.3 PIPELINE PRODUCT PORTFOLIO

16.27.4 RECENT DEVELOPMENT

16.28 NOVOMEDIX

16.28.1 COMPANY SNAPSHOT

16.28.2 PIPELINE PRODUCT PORTFOLIO

16.28.3 RECENT DEVELOPMENT

16.29 PILANT THERAPEUTICS, INC.

16.29.1 COMPANY SNAPSHOT

16.29.2 REVENUE ANALYSIS

16.29.3 PIPELINE PRODUCT PORTFOLIO

16.29.4 RECENT NEWS

16.3 PFIZER INC.

16.30.1 COMPANY SNAPSHOT

16.30.2 REVENUE ANALYSIS

16.30.3 PIPELINE PRODUCT PORTFOLIO

16.30.4 RECENT DEVELOPMENT/NEWS

16.31 SAGIMET BIOSCIENCES

16.31.1 COMPANY SNAPSHOTS

16.31.2 REVENUE ANALYSIS

16.31.3 1.1.4 PRODUCT PORTFOLIO

16.31.4 RECENT DEVELOPMENT/NEWS

16.32 TAKEDA PHARMACEUTICAL COMPANY LIMITED

16.32.1 COMPANY SNAPSHOT

16.32.2 REVENUE ANALYSIS

16.32.3 PIPELINE PRODUCT PORTFOLIO

16.32.4 PRODUCT PORTFOLIO

16.32.5 RECENT DEVELOPMENT

16.33 TVARDI THERAPEUTICS

16.33.1 COMPANY SNAPSHOT

16.33.2 PIPELINE PRODUCT PORTFOLIO

16.33.3 RECENT DEVELOPMENT/NEWS

16.34 VERTEX PHARMACEUTICALS INCORPORATED

16.34.1 COMPANY SNAPSHOT

16.34.2 REVENUE ANALYSIS

16.34.3 PRODUCT PORTFOLIO

16.34.4 RECENT DEVELOPMENT

16.35 VIKING THERAPEUTICS

16.35.1 COMPANY SNAPSHOT

16.35.2 REVENUE ANALYSIS

16.35.3 PIPELINE PRODUCT PORTFOLIO

16.35.4 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

Список таблиц

TABLE 1 EUROPE INCIDENCE OF CIRRHOSIS BY GENDER (2019)

TABLE 2 TREATMENT ADHERENCE LEVELS IN LIVER DISEASE PATIENTS

TABLE 3 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 4 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 5 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 6 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 7 EUROPE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 8 EUROPE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 9 EUROPE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 10 EUROPE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 11 EUROPE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 12 EUROPE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 13 EUROPE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 14 EUROPE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 15 EUROPE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 16 EUROPE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 17 EUROPE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 18 EUROPE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 19 EUROPE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 20 EUROPE INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 EUROPE INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 22 EUROPE INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 23 EUROPE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 24 EUROPE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 25 EUROPE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 26 EUROPE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 27 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 28 EUROPE MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 29 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 30 EUROPE BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 31 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 32 EUROPE SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 33 EUROPE SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 34 EUROPE LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 35 EUROPE ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 36 EUROPE LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 37 EUROPE PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 38 EUROPE CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 39 EUROPE STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 40 EUROPE GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 41 EUROPE HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 42 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 43 EUROPE F2 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 44 EUROPE F1 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 45 EUROPE F3 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 46 EUROPE F4 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 47 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 48 EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 49 EUROPE HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 50 EUROPE HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 51 EUROPE ALCOHOLIC LIVER DISEASE (ALD) IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 52 EUROPE AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 53 EUROPE AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 54 EUROPE GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 55 EUROPE GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 56 EUROPE OTHERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 57 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 58 EUROPE MALE IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 59 EUROPE MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 60 EUROPE FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 61 EUROPE FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 62 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 63 EUROPE HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 64 EUROPE HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 65 EUROPE SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 66 EUROPE SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 EUROPE CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 68 EUROPE AMBULATORY AND RESEARCH CENTERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 69 EUROPE OTHERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 70 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 71 EUROPE DIRECT TENDER IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 72 EUROPE RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 73 EUROPE RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 74 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 75 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 76 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 77 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 78 EUROPE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 79 EUROPE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 80 EUROPE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 81 EUROPE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 EUROPE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 83 EUROPE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 84 EUROPE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 85 EUROPE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 86 EUROPE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 87 EUROPE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 88 EUROPE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 89 EUROPE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 90 EUROPE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 91 EUROPE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 92 EUROPE INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 93 EUROPE INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 94 TYPE

TABLE 95 EUROPE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 96 EUROPE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 97 EUROPE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 98 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 99 EUROPE MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 100 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 101 EUROPE BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 102 EUROPE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 103 EUROPE SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 104 EUROPE LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 105 EUROPE ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 106 EUROPE LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 107 EUROPE PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 108 EUROPE CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 EUROPE STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 110 EUROPE GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 EUROPE HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 112 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 113 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 114 EUROPE HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 115 EUROPE AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 116 EUROPE GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 117 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 118 EUROPE MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 119 EUROPE FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 120 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 121 EUROPE HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 122 EUROPE SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 123 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 124 EUROPE RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 GERMANY LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 GERMANY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 127 GERMANY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 128 GERMANY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 129 GERMANY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 130 GERMANY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 131 GERMANY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 132 GERMANY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 133 GERMANY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 134 GERMANY ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 135 GERMANY ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 136 GERMANY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 GERMANY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 138 GERMANY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 139 GERMANY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 GERMANY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 141 GERMANY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 142 GERMANY INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 143 GERMANY INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 144 GERMANY INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 145 GERMANY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 146 GERMANY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 147 GERMANY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 148 GERMANY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 149 GERMANY MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 GERMANY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 151 GERMANY BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 152 GERMANY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 153 GERMANY SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 GERMANY LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 GERMANY ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 156 GERMANY LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 157 GERMANY PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 158 GERMANY CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 159 GERMANY STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 160 GERMANY GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 GERMANY HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 162 GERMANY LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 163 GERMANY LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 164 GERMANY HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 165 GERMANY AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 166 GERMANY GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 167 GERMANY LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 168 GERMANY MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 GERMANY FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 170 GERMANY LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 171 GERMANY HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 172 GERMANY SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 173 GERMANY LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 174 GERMANY RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 FRANCE LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 176 FRANCE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 177 FRANCE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 178 FRANCE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 FRANCE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 180 FRANCE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 181 FRANCE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 FRANCE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 183 FRANCE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 184 FRANCE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 185 FRANCE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 186 FRANCE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 187 FRANCE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 188 FRANCE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 189 FRANCE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 FRANCE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 191 FRANCE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 192 FRANCE INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 193 FRANCE INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 194 FRANCE INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 195 FRANCE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 FRANCE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 197 FRANCE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 198 FRANCE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 199 FRANCE MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 200 FRANCE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 201 FRANCE BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 202 FRANCE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 203 FRANCE SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 204 FRANCE LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 FRANCE ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 206 FRANCE LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 207 FRANCE PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 FRANCE CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 209 FRANCE STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 210 FRANCE GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 FRANCE HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 212 FRANCE LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 213 FRANCE LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 214 FRANCE HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 FRANCE AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 216 FRANCE GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 FRANCE LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 218 FRANCE MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 FRANCE FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 FRANCE LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 221 FRANCE HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 222 FRANCE SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 FRANCE LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 224 FRANCE RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 U.K. LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 226 U.K. MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 U.K. MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 228 U.K. ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 229 U.K. ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 230 U.K. ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 231 U.K. ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 232 U.K. ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 233 U.K. ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 234 U.K. ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 235 U.K. ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 236 U.K. CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 237 U.K. CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 238 U.K. CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 239 U.K. TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 240 U.K. TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 241 U.K. TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 242 U.K. INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 243 U.K. INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 244 U.K. INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 245 U.K. IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 U.K. IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 247 U.K. IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 248 U.K. MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 249 U.K. MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 250 U.K. MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 251 U.K. BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 U.K. MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 253 U.K. SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 254 U.K. LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 255 U.K. ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 U.K. LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 257 U.K. PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 258 U.K. CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 259 U.K. STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 260 U.K. GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 261 U.K. HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 262 U.K. LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 263 U.K. LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 264 U.K. HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 265 U.K. AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 U.K. GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 267 U.K. LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 268 U.K. MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 U.K. FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 U.K. LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 271 U.K. HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 272 U.K. SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 U.K. LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 274 U.K. RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 275 ITALY LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 276 ITALY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 277 ITALY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 278 ITALY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 ITALY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 280 ITALY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 281 ITALY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 282 ITALY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 283 ITALY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 284 ITALY ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 ITALY ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 286 ITALY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 287 ITALY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 288 ITALY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 289 ITALY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 290 ITALY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 291 ITALY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 292 ITALY INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 293 ITALY INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 294 ITALY INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 295 ITALY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 296 ITALY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 297 ITALY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 298 ITALY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 299 ITALY MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 ITALY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 301 ITALY BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 302 ITALY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 303 ITALY SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 304 ITALY LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 ITALY ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 ITALY LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 307 ITALY PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 308 ITALY CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 309 ITALY STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 310 ITALY GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 311 ITALY HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 312 ITALY LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 313 ITALY LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 314 ITALY HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 315 ITALY AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 316 ITALY GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 317 ITALY LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 318 ITALY MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 319 ITALY FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 320 ITALY LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 321 ITALY HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 322 ITALY SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 323 ITALY LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 324 ITALY RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 325 SPAIN LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 326 SPAIN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 SPAIN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 328 SPAIN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 SPAIN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 330 SPAIN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 331 SPAIN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 332 SPAIN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 333 SPAIN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 334 SPAIN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 335 SPAIN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 336 SPAIN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 SPAIN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 338 SPAIN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 339 SPAIN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 340 SPAIN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 341 SPAIN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 342 SPAIN INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 343 SPAIN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 344 SPAIN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 345 SPAIN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 346 SPAIN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 347 SPAIN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 348 SPAIN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 349 SPAIN MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 SPAIN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 SPAIN BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 352 SPAIN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 353 SPAIN SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 354 SPAIN LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 355 SPAIN ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 SPAIN LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 SPAIN PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 358 SPAIN CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 359 SPAIN STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 360 SPAIN GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 361 SPAIN HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 SPAIN LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 363 SPAIN LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 364 SPAIN HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 365 SPAIN AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 366 SPAIN GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 367 SPAIN LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 368 SPAIN MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 369 SPAIN FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 370 SPAIN LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 371 SPAIN HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 SPAIN SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 373 SPAIN LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 374 SPAIN RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 375 SWITZERLAND LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 376 SWITZERLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 377 SWITZERLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 378 SWITZERLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 379 SWITZERLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 380 SWITZERLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 381 SWITZERLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 382 SWITZERLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 383 SWITZERLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 384 SWITZERLAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 385 SWITZERLAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 386 SWITZERLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 387 SWITZERLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 388 SWITZERLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 389 SWITZERLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 390 SWITZERLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 391 SWITZERLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 392 SWITZERLAND INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 393 SWITZERLAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 394 SWITZERLAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 395 SWITZERLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 396 SWITZERLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 397 SWITZERLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 398 SWITZERLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 399 SWITZERLAND MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 400 SWITZERLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 401 SWITZERLAND BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 402 SWITZERLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 403 SWITZERLAND SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 404 SWITZERLAND LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 405 SWITZERLAND ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 406 SWITZERLAND LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 407 SWITZERLAND PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 408 SWITZERLAND CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 409 SWITZERLAND STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 410 SWITZERLAND GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 411 SWITZERLAND HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 412 SWITZERLAND LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 413 SWITZERLAND LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 414 SWITZERLAND HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 415 SWITZERLAND AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 416 SWITZERLAND GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 417 SWITZERLAND LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 418 SWITZERLAND MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 419 SWITZERLAND FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 420 SWITZERLAND LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 421 SWITZERLAND HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 422 SWITZERLAND SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 423 SWITZERLAND LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 424 SWITZERLAND RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 425 RUSSIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 426 RUSSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 427 RUSSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 428 RUSSIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 429 RUSSIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 430 RUSSIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 431 RUSSIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 432 RUSSIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 433 RUSSIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 434 RUSSIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 435 RUSSIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 436 RUSSIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 437 RUSSIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 438 RUSSIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 439 RUSSIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 440 RUSSIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 441 RUSSIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 442 RUSSIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 443 RUSSIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 444 RUSSIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 445 RUSSIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 446 RUSSIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 447 RUSSIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 448 RUSSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 449 RUSSIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 450 RUSSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 451 RUSSIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 452 RUSSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 453 RUSSIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 454 RUSSIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 455 RUSSIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 456 RUSSIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 457 RUSSIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 458 RUSSIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 459 RUSSIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 460 RUSSIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 461 RUSSIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 462 RUSSIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 463 RUSSIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 464 RUSSIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 465 RUSSIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 466 RUSSIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 467 RUSSIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 468 RUSSIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 469 RUSSIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 470 RUSSIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 471 RUSSIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 472 RUSSIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 473 RUSSIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 474 RUSSIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 475 BELGIUM LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 476 BELGIUM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 477 BELGIUM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 478 BELGIUM ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 479 BELGIUM ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 480 BELGIUM ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 481 BELGIUM ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 482 BELGIUM ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 483 BELGIUM ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 484 BELGIUM ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 485 BELGIUM ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 486 BELGIUM CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 487 BELGIUM CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 488 BELGIUM CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 489 BELGIUM TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 490 BELGIUM TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 491 BELGIUM TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 492 BELGIUM INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 493 BELGIUM INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 494 BELGIUM INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 495 BELGIUM IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 496 BELGIUM IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 497 BELGIUM IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 498 BELGIUM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 499 BELGIUM MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 500 BELGIUM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 501 BELGIUM BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 502 BELGIUM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 503 BELGIUM SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 504 BELGIUM LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 505 BELGIUM ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 506 BELGIUM LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 507 BELGIUM PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 508 BELGIUM CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 509 BELGIUM STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 510 BELGIUM GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 511 BELGIUM HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 512 BELGIUM LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 513 BELGIUM LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 514 BELGIUM HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 515 BELGIUM AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 516 BELGIUM GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 517 BELGIUM LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 518 BELGIUM MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 519 BELGIUM FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 520 BELGIUM LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 521 BELGIUM HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 522 BELGIUM SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 523 BELGIUM LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 524 BELGIUM RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 525 NETHERLANDS LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 526 NETHERLANDS MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 527 NETHERLANDS MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 528 NETHERLANDS ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 529 NETHERLANDS ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 530 NETHERLANDS ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 531 NETHERLANDS ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 532 NETHERLANDS ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 533 NETHERLANDS ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 534 NETHERLANDS ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 535 NETHERLANDS ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 536 NETHERLANDS CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 537 NETHERLANDS CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 538 NETHERLANDS CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 539 NETHERLANDS TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 540 NETHERLANDS TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 541 NETHERLANDS TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 542 NETHERLANDS INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 543 NETHERLANDS INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 544 NETHERLANDS INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 545 NETHERLANDS IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 546 NETHERLANDS IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 547 NETHERLANDS IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 548 NETHERLANDS MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 549 NETHERLANDS MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 550 NETHERLANDS MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 551 NETHERLANDS BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 552 NETHERLANDS MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 553 NETHERLANDS SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 554 NETHERLANDS LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 555 NETHERLANDS ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 556 NETHERLANDS LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 557 NETHERLANDS PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 558 NETHERLANDS CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 559 NETHERLANDS STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 560 NETHERLANDS GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 561 NETHERLANDS HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 562 NETHERLANDS LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 563 NETHERLANDS LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 564 NETHERLANDS HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 565 NETHERLANDS AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 566 NETHERLANDS GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 567 NETHERLANDS LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 568 NETHERLANDS MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 569 NETHERLANDS FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 570 NETHERLANDS LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 571 NETHERLANDS HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 572 NETHERLANDS SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 573 NETHERLANDS LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 574 NETHERLANDS RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 575 TURKEY LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 576 TURKEY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 577 TURKEY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 578 TURKEY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 579 TURKEY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 580 TURKEY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 581 TURKEY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 582 TURKEY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 583 TURKEY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 584 TURKEY ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 585 TURKEY ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 586 TURKEY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 587 TURKEY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 588 TURKEY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 589 TURKEY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 590 TURKEY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 591 TURKEY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 592 TURKEY INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 593 TURKEY INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 594 TURKEY INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 595 TURKEY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 596 TURKEY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 597 TURKEY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 598 TURKEY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 599 TURKEY MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 600 TURKEY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 601 TURKEY BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 602 TURKEY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 603 TURKEY SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 604 TURKEY LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 605 TURKEY ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 606 TURKEY LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 607 TURKEY PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 608 TURKEY CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 609 TURKEY STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 610 TURKEY GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 611 TURKEY HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 612 TURKEY LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 613 TURKEY LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 614 TURKEY HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 615 TURKEY AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 616 TURKEY GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 617 TURKEY LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 618 TURKEY MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 619 TURKEY FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 620 TURKEY LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 621 TURKEY HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 622 TURKEY SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 623 TURKEY LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 624 TURKEY RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 625 POLAND LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 626 POLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 627 POLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 628 POLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 629 POLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 630 POLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 631 POLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 632 POLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 633 POLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 634 POLAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 635 POLAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 636 POLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 637 POLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 638 POLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 639 POLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 640 POLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 641 POLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 642 POLAND INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 643 POLAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 644 POLAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 645 POLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 646 POLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 647 POLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 648 POLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 649 POLAND MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 650 POLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 651 POLAND BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 652 POLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 653 POLAND SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 654 POLAND LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 655 POLAND ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 656 POLAND LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 657 POLAND PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 658 POLAND CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 659 POLAND STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 660 POLAND GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 661 POLAND HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 662 POLAND LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 663 POLAND LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 664 POLAND HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 665 POLAND AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 666 POLAND GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 667 POLAND LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 668 POLAND MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 669 POLAND FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 670 POLAND LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 671 POLAND HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 672 POLAND SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 673 POLAND LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 674 POLAND RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 675 SWEDEN LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 676 SWEDEN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 677 SWEDEN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 678 SWEDEN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 679 SWEDEN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 680 SWEDEN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 681 SWEDEN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 682 SWEDEN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 683 SWEDEN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 684 SWEDEN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 685 SWEDEN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 686 SWEDEN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 687 SWEDEN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 688 SWEDEN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 689 SWEDEN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 690 SWEDEN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 691 SWEDEN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 692 SWEDEN INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 693 SWEDEN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 694 SWEDEN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 695 SWEDEN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 696 SWEDEN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 697 SWEDEN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 698 SWEDEN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 699 SWEDEN MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 700 SWEDEN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 701 SWEDEN BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 702 SWEDEN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 703 SWEDEN SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 704 SWEDEN LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 705 SWEDEN ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 706 SWEDEN LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 707 SWEDEN PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 708 SWEDEN CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 709 SWEDEN STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 710 SWEDEN GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 711 SWEDEN HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 712 SWEDEN LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 713 SWEDEN LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 714 SWEDEN HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 715 SWEDEN AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 716 SWEDEN GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 717 SWEDEN LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 718 SWEDEN MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 719 SWEDEN FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 720 SWEDEN LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 721 SWEDEN HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 722 SWEDEN SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 723 SWEDEN LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 724 SWEDEN RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 725 NORWAY LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 726 NORWAY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 727 NORWAY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 728 NORWAY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 729 NORWAY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 730 NORWAY ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 731 NORWAY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 732 NORWAY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 733 NORWAY ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 734 NORWAY ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 735 NORWAY ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 736 NORWAY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 737 NORWAY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 738 NORWAY CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 739 NORWAY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 740 NORWAY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 741 NORWAY TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 742 NORWAY INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 743 NORWAY INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 744 NORWAY INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 745 NORWAY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 746 NORWAY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 747 NORWAY IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 748 NORWAY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 749 NORWAY MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 750 NORWAY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 751 NORWAY BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 752 NORWAY MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 753 NORWAY SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 754 NORWAY LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 755 NORWAY ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 756 NORWAY LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 757 NORWAY PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 758 NORWAY CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 759 NORWAY STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 760 NORWAY GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 761 NORWAY HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 762 NORWAY LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 763 NORWAY LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 764 NORWAY HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 765 NORWAY AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 766 NORWAY GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 767 NORWAY LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 768 NORWAY MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 769 NORWAY FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 770 NORWAY LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 771 NORWAY HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 772 NORWAY SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 773 NORWAY LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 774 NORWAY RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 775 DENMARK LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 776 DENMARK MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 777 DENMARK MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 778 DENMARK ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 779 DENMARK ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 780 DENMARK ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 781 DENMARK ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 782 DENMARK ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 783 DENMARK ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 784 DENMARK ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 785 DENMARK ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 786 DENMARK CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 787 DENMARK CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 788 DENMARK CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 789 DENMARK TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 790 DENMARK TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 791 DENMARK TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 792 DENMARK INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 793 DENMARK INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 794 DENMARK INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 795 DENMARK IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 796 DENMARK IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 797 DENMARK IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 798 DENMARK MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 799 DENMARK MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 800 DENMARK MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 801 DENMARK BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 802 DENMARK MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 803 DENMARK SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 804 DENMARK LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 805 DENMARK ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 806 DENMARK LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 807 DENMARK PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 808 DENMARK CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 809 DENMARK STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 810 DENMARK GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 811 DENMARK HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 812 DENMARK LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 813 DENMARK LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 814 DENMARK HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 815 DENMARK AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 816 DENMARK GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 817 DENMARK LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 818 DENMARK MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 819 DENMARK FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 820 DENMARK LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 821 DENMARK HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 822 DENMARK SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 823 DENMARK LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 824 DENMARK RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 825 FINLAND LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 826 FINLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 827 FINLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 828 FINLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 829 FINLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 830 FINLAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 831 FINLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 832 FINLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 833 FINLAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 834 FINLAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 835 FINLAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 836 FINLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 837 FINLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 838 FINLAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 839 FINLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 840 FINLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 841 FINLAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 842 FINLAND INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 843 FINLAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 844 FINLAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 845 FINLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 846 FINLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 847 FINLAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 848 FINLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 849 FINLAND MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 850 FINLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 851 FINLAND BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 852 FINLAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 853 FINLAND SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 854 FINLAND LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 855 FINLAND ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 856 FINLAND LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 857 FINLAND PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 858 FINLAND CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 859 FINLAND STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 860 FINLAND GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 861 FINLAND HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 862 FINLAND LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 863 FINLAND LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 864 FINLAND HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 865 FINLAND AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 866 FINLAND GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 867 FINLAND LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 868 FINLAND MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 869 FINLAND FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 870 FINLAND LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 871 FINLAND HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 872 FINLAND SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 873 FINLAND LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 874 FINLAND RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 875 REST OF EUROPE LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

Список рисунков

FIGURE 1 EUROPE LIVER FIBROSIS TREATMENT MARKET: SEGMENTATION

FIGURE 2 EUROPE LIVER FIBROSIS TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE LIVER FIBROSIS TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 EUROPE LIVER FIBROSIS TREATMENT MARKET: REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE LIVER FIBROSIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE LIVER FIBROSIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE LIVER FIBROSIS TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE LIVER FIBROSIS TREATMENT MARKET: MARKET END USER COVERAGE GRID..

FIGURE 9 EUROPE LIVER FIBROSIS TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE LIVER FIBROSIS TREATMENT MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE OF LIVER DISEASES IS EXPECTED TO DRIVE THE GROWTH OF EUROPE LIVER FIBROSIS TREATMENT MARKET FROM 2025 TO 2032

FIGURE 12 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LIVER FIBROSIS TREATMENT MARKET IN 2025-2032

FIGURE 13 TWO SEGMENTS COMPRISE THE EUROPE LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE

FIGURE 14 EUROPE LIVER FIBROSIS TREATMENT MARKET: EXECUTIVE SUMMARY

FIGURE 15 STRATEGIC DECISIONS

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE LIVER FIBROSIS TREATMENT MARKET

FIGURE 17 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, 2024

FIGURE 18 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)

FIGURE 19 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)

FIGURE 20 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 21 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY STAGES, 2024

FIGURE 22 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY STAGES, 2025-2032 (USD THOUSAND)

FIGURE 23 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY STAGES, CAGR (2025-2032)

FIGURE 24 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY STAGES, LIFELINE CURVE

FIGURE 25 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, 2024

FIGURE 26 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, 2025-2032 (USD THOUSAND)

FIGURE 27 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, CAGR (2025-2032)

FIGURE 28 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 29 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY GENDER, 2024

FIGURE 30 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)

FIGURE 31 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY GENDER, CAGR (2025-2032)

FIGURE 32 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 33 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY END USER, 2024

FIGURE 34 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)

FIGURE 35 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY END USER, CAGR (2025-2032)

FIGURE 36 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 37 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2024

FIGURE 38 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)

FIGURE 39 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)

FIGURE 40 EUROPE LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 41 EUROPE LIVER FIBROSIS TREATMENT MARKET: SNAPSHOT (2024)

FIGURE 42 EUROPE LIVER FIBROSIS TREATMENT MARKET: COMPANY SHARE 2024 (%)

View Detailed Information

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

What is the current market size of the Europe liver fibrosis treatment market?

The Europe liver fibrosis treatment market size was valued at USD 5.06 billion in 2024.

What is the expected growth rate of Europe liver fibrosis treatment market ?

The Europe liver fibrosis treatment market is to grow at a CAGR of 10.3% during the forecast period of 2025 to 2032.

What are the primary segments covered in the Europe liver fibrosis treatment market ?

The Europe liver fibrosis treatment market is segmented into five notable segments based on treatment type, stages, indication, end user, and distribution channel. On the basis of treatment type, the market is segmented into medication and surgery/therapy. on the basis of stages, the market is segmented into F2, F1, F3, and F4, on the basis of indication, the market is segmented into non-alcoholic steatohepatitis (Nash), hepatitis B & C-induced fibrosis, alcoholic liver disease (ALD), autoimmune liver diseases, genetic disorders, and others. on the basis of gender, the market is segmented into male and female. on the basis of end user, the market is segmented into hospitals, specialty clinics, clinics, ambulatory and research centers, and others. on the basis of distribution channel, the market is segmented into direct tender and retail sales.

Who are major players in Europe liver fibrosis treatment ?

Companies such as Gilead Sciences, Inc. (U.S.),AbbVie Inc. (U.S.),Merck & Co., Inc. (U.S.),Novartis AG (Switzerland), Intercept Pharmaceuticals, Inc. (U.S.)are the major companies in the europe liver fibrosis treatment.

What are the recent product launches by major companies in the europe liver fibrosis treatment ?

In October 2024, Intercept Pharmaceuticals, Inc discussed their ongoing efforts to explore racial differences and disparities in Primary Biliary Cholangitis (PBC) care. The company is addressing how various populations may face different challenges in the diagnosis, treatment, and management of PBC. By exploring these disparities, Intercept aims to improve access to care and treatment outcomes for all patients, potentially reducing barriers to effective treatment of liver diseases, including fibrosis.

Which countries data is covered in the Europe liver fibrosis treatment ?

The countries covered in the Europe liver fibrosis treatment are Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Netherlands, Switzerland, Norway, Austria, Ireland, and rest of Europe.

Which country is expected to dominate in the Europe liver fibrosis treatment ?

Germany is expected to dominate the Europe liver fibrosis treatment market, particularly in North America, due to advanced healthcare infrastructure, high disease prevalence, robust research funding, presence of leading pharmaceutical companies, and rapid adoption of innovative treatment solutions.

Which country is expected to witness the highest CAGR in Europe liver fibrosis treatment ?

Germany is expected to witness the highest CAGR in the Europe liver fibrosis treatment market, driven by rising disease prevalence, healthcare reforms, and increased R&D.

What are the major challenges in the Europe liver fibrosis treatment ?

The primary challenges include long-term follow-ups associated with liver fibrosis treatment, high costs, limited curative options, and patient adherence issues.

What are the key trends in the Europe liver fibrosis treatment ?

Increasing prevalence of liver diseases , is emerging as a pivotal trend driving the Europe liver fibrosis treatment.

What are the factors driving the Europe liver fibrosis treatment growth?

The major factors driving the growth of Europe liver fibrosis treatment are rising consumption of alcohol, rising liver transplantation rates, and growing incidence of non-alcoholic fatty liver disease (NAFLD) & NASH.

Which is the dominating segment in the Europe liver fibrosis treatment ?

The treatment type segment is expected to dominate the Europe liver fibrosis treatment market in 2025 due to increasing demand for effective therapies, ongoing clinical trials, and rising approvals of novel drugs.

Отчет об анализе размера, доли и тенденций европейского рынка лечения фиброза печени – обзор отрасли и прогноз до 2032 года

Обходите тарифные трудности с помощью гибкого консалтинга в области цепочки поставок

Europe Liver Fibrosis Treatment Market

CAGR : 10.30 %

Размер рынка лечения фиброза печени в Европе

Анализ рынка лечения фиброза печени в Европе

Объем рынка лечения фиброза печени в Европе

Доля рынка лечения фиброза печени в Европе

Последние разработки на европейском рынке лечения фиброза печени

Get online access to the report on the World's First Market Intelligence Cloud

Содержание

Список таблиц

Список рисунков

Методология исследования

Доступна настройка

Часто задаваемые вопросы

Отчеты

Обзор рынка

Поддерживать

Решения

Отчет об анализе размера, доли и тенденций европейского рынка лечения фиброза печени – обзор отрасли и прогноз до 2032 года

Обходите тарифные трудности с помощью гибкого консалтинга в области цепочки поставок

Europe Liver Fibrosis Treatment Market

CAGR : 10.30 %

Размер рынка лечения фиброза печени в Европе

Анализ рынка лечения фиброза печени в Европе

Объем рынка лечения фиброза печени в Европе

Доля рынка лечения фиброза печени в Европе

Последние разработки на европейском рынке лечения фиброза печени

Get online access to the report on the World's First Market Intelligence Cloud

Содержание

Список таблиц

Список рисунков

Методология исследования

Доступна настройка

Часто задаваемые вопросы

Просмотр связанных страниц